AUTHORS: Jan Twombly and Jeff Shuman
Three trends – new technologies, shifting economics, and empowered patients – are disrupting biopharma’s traditional business model. Smart biopharma companies are responding by embracing a holistic “beyond the pill” approach to the future.
For most biopharma companies, beyond the pill is largely a defensive strategy aimed at justifying or preserving pricing or perhaps gaining reimbursement in any amount. If prognosticators are correct, this bundle of product, services, and data (typically referred to as a solution) will be required for receiving regulatory approval in the not-to-distant future. The bundle may even be part of a single label.
Opportunities to create, deliver, and capture value abound across the value chain. All require partnering. Biopharma partnering and alliance professionals should dive in, head first.